Prescribing a controlled substance to a patient seen via telehealth involves at least three layers of rules that need to line up at once: the physician's DEA registration, the state's own controlled-substance requirements, and whatever federal telehealth-specific flexibilities are currently in effect. None of the three substitutes for the other two.
The federal layer
DEA registration authorizes controlled-substance prescribing generally, but telehealth prescribing specifically has, since 2020, operated under temporary flexibilities that permit prescribing without a prior in-person evaluation in many circumstances. These flexibilities have been extended repeatedly rather than made permanent, and a proposed special registration rule for telemedicine remains unfinalized.
The state layer
On top of the federal baseline, most states maintain their own controlled-substance registration requirements, often tied to querying a state prescription drug monitoring program before prescribing. Some states impose additional restrictions — for example, limiting Schedule II prescribing via telehealth to narrower circumstances than federal flexibilities would otherwise allow. State rules can be stricter than the federal floor but generally cannot be looser.
Federal telehealth flexibilities set a floor, not a ceiling — a state can still impose stricter controlled-substance rules on top of it.
What to check before prescribing
Before prescribing a controlled substance via telehealth, physicians generally confirm: that DEA registration is current and covers the relevant schedule, that any state-specific controlled-substance registration or PDMP query requirement has been satisfied, and that the current federal telehealth flexibility actually covers the prescribing scenario at hand rather than assuming it does.
Check current prescribing rules by state →Requirements vary by state and change over time — always confirm current requirements directly with the relevant state board or agency before making a compliance decision.